Russia Approves Second Coronavirus Vaccine after Preliminary Trials

Russia has approved the second Coronavirus Vaccine after preliminary trials.

The announcement was made by the Russian President Vladimir Putin in a government meeting on Wednesday.

“We need to increase production of the first and second vaccine,” Putin said in comments aired on the state TV.

“We are continuing to cooperate with our foreign partners and will promote our vaccine abroad.”

Read More: Russia gives a final approval to first coronavirus vaccine for sale in pharmacies

As being reported,  jab was developed by the Vector Institute in Siberia and it completed early-stage human trials last month.

However, results have not been published yet and a large-scale trial, known as Phase III, has not yet started.

As being reported, the peptide-based vaccine, named EpiVacCorona, is the second to be licensed for use in Russia.

There has been reportedly  a placebo-controlled trial on 100 volunteers between 18 and 60 in Novosibirsk.

According to the news source, a large-scale human trial of EpiVacCorona is likely to begin in November or December.

However, TASS news agency cited that the consumer safety watchdog Rospotrebnadzor, which supervises the institute, as saying this month.

According to the Interfax news agency, the trial is expected to involve 30,000 volunteers, of whom the first 5,000 will be residents of Siberia.

A shot developed by Moscow’s Gamaleya Institute, Sputnik V, was the first coronavirus vaccine licensed for domestic use in August.

Sputnik V, based on an adenovirus vector, was also registered before Phase III trials. As beigng reported, a trial involving 40,000 participants is now under way in Moscow.